share_log

Assembly Biosciences | 10-Q: Q2 2024 Earnings Report

Assembly Biosciences | 10-Q: Q2 2024 Earnings Report

Assembly Biosciences | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/09 04:22

Moomoo AI 已提取核心信息

Assembly Biosciences reported Q2 2024 financial results with collaboration revenue of $8.5 million from the Gilead agreement, compared to no revenue in Q2 2023. Net loss was $11.2 million or $1.98 per share, improved from a $16.9 million loss or $3.88 per share in the prior year period. Research and development expenses increased 30% to $16.3 million due to advancement of key programs.The company ended the quarter with $109.2 million in cash, cash equivalents and marketable securities. During Q2, Assembly raised $12.4 million through a registered direct offering and private placement, including shares and warrants sold to Gilead to maintain its 19.9% ownership stake. General and administrative expenses decreased 10% to $4.5 million.Assembly advanced multiple clinical programs, including initiating Phase 1 studies for ABI-5366 in recurrent genital herpes and ABI-4334 for chronic HBV infection. The company expects to begin additional Phase 1 trials by year-end for ABI-6250 in HDV and ABI-1179 in recurrent genital herpes. Management believes current funding will support operations into 2026.
Assembly Biosciences reported Q2 2024 financial results with collaboration revenue of $8.5 million from the Gilead agreement, compared to no revenue in Q2 2023. Net loss was $11.2 million or $1.98 per share, improved from a $16.9 million loss or $3.88 per share in the prior year period. Research and development expenses increased 30% to $16.3 million due to advancement of key programs.The company ended the quarter with $109.2 million in cash, cash equivalents and marketable securities. During Q2, Assembly raised $12.4 million through a registered direct offering and private placement, including shares and warrants sold to Gilead to maintain its 19.9% ownership stake. General and administrative expenses decreased 10% to $4.5 million.Assembly advanced multiple clinical programs, including initiating Phase 1 studies for ABI-5366 in recurrent genital herpes and ABI-4334 for chronic HBV infection. The company expects to begin additional Phase 1 trials by year-end for ABI-6250 in HDV and ABI-1179 in recurrent genital herpes. Management believes current funding will support operations into 2026.
Assembly Biosciences报告了2024年第二季度的财务结果，来自吉利德协议的合作营业收入为850万美元，而2023年第二季度没有任何收入。净亏损为1120万美元，或每股1.98美元，较去年同期的1690万美元亏损或每股3.88美元有所改善。由于关键项目的推进，研发支出增加了30%，达到1630万美元。公司季度末现金、现金等价物和可交易证券为10920万美元。在第二季度，Assembly通过注册直接发行和定向增发筹集了1240万美元，包括出售给吉利德的股份和Warrants，以维持其19.9%的股权。一般和行政费用减少了10%，降至450万美元。Assembly推进了多个临床项目，包括启动针对复发性生殖器疱疹的ABI-5366和针对慢性HBV感染的ABI-4334的第一阶段研究。公司预计将在年底前开始针对HDV的ABI-6250和复发性生殖器疱疹的ABI-1179的额外第一阶段试验。管理层相信，目前的资金将支持运营到2026年。
Assembly Biosciences报告了2024年第二季度的财务结果，来自吉利德协议的合作营业收入为850万美元，而2023年第二季度没有任何收入。净亏损为1120万美元，或每股1.98美元，较去年同期的1690万美元亏损或每股3.88美元有所改善。由于关键项目的推进，研发支出增加了30%，达到1630万美元。公司季度末现金、现金等价物和可交易证券为10920万美元。在第二季度，Assembly通过注册直接发行和定向增发筹集了1240万美元，包括出售给吉利德的股份和Warrants，以维持其19.9%的股权。一般和行政费用减少了10%，降至450万美元。Assembly推进了多个临床项目，包括启动针对复发性生殖器疱疹的ABI-5366和针对慢性HBV感染的ABI-4334的第一阶段研究。公司预计将在年底前开始针对HDV的ABI-6250和复发性生殖器疱疹的ABI-1179的额外第一阶段试验。管理层相信，目前的资金将支持运营到2026年。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日